For Admin

Japanese

A Leading Company in Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

For Absorption

For Vaccination

For Nose-to-Brain

3D Nasal Cast Model

News

2020｜2019｜2018｜2016｜2015｜2014｜2013｜2012〜

February 03, 2020

Satsuma Pharmaceuticals, Inc. Announces Publication of STS101 Phase 1 Clinical Trial Results in Headache: The Journal of Head and Face Pain

September 17, 2019

Satsuma Pharmaceuticals, Inc. Listed on NASDAQ

August 23, 2019

Satsuma Pharmaceuticals, Inc. Announces First Patient Dosed in EMERGE™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

April 25, 2019

Satsuma Pharmaceuticals, Inc. Raises $62 Million in Series B Preferred Stock Financing

February 21, 2019

Satsuma Pharmaceuticals, Inc. announces advance of lead product candidate, STS101, into Phase 3 Efficacy Trial for Acute Migraine in 2019

June 19, 2018

Event: SNBL will exhibit a booth showcasing our nasal delivery technology at WCP 2018 KYOTO

June 15, 2018

Event: SNBL to present in vitro/in vivo evaluations of proprietary Nose-to-Brain delivery technology at CRS Annual Meeting 2018

April 2, 2018

December 19, 2016

Satsuma Pharmaceuticals Inc., Completes Third-party Allocation of New Shares - $12M Financing Accelerates Development of Migraine Therapeutic -

2020｜2019｜2018｜2016｜2015｜2014｜2013｜2012〜